Navigation Links
BD Completes Acquisition of Carmel Pharma
Date:8/16/2011

FRANKLIN LAKES, N.J., Aug. 16, 2011 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the completion of its acquisition of Carmel Pharma, AB, a Swedish company that manufactures the PhaSeal® System, the leading closed-system drug transfer device for the safe handling of hazardous drugs that are packaged in vials.  The acquisition expands the scope of BD's healthcare worker safety emphasis to include hazardous drug exposure reduction.

"Carmel Pharma is a leader in an early-stage market with significant long-term growth potential," said Alberto Mas, President, BD Medical – Medical Surgical Systems. "We're excited to begin moving forward to address the critically important issue of hazardous drug exposure to healthcare providers by raising awareness, driving advocacy efforts, developing pharmacy and nursing relationships, and expanding market reach around the world for this product category."

"We are pleased to welcome this new platform and these new associates to BD," said Alexandre Conroy, President, BD – Western Europe. "Healthcare worker safety is an important focus for BD in Europe, and globally. Through this acquisition, BD will be able to provide an enhanced suite of safety products to our customers."

The Company expects fully diluted earnings per share to be adversely impacted by the acquisition in fiscal year 2011 by approximately $0.05, which was not included in the fiscal year 2011 earnings guidance the Company provided in connection with the release of its third fiscal quarter earnings.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world.  BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding the potential benefits of the acquisition that BD expects to occur or anticipates occurring in the future.  All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties.  Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement.  With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: the ability to successfully integrate Carmel Pharma's operations and programs with BD's and the time and resources required to do so; difficulties inherent in product development and delays in product introductions; competitive factors; pricing and market pressures; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; as well as other factors discussed in BD's filings with the Securities and Exchange Commission.  We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

Contacts:
Colleen T. White, Corporate Communications – 201-847-5369
Colleen_white@bd.com

Monique N. Dolecki, Investor Relations – 201-847-5453
Monique_dolecki@bd.com


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
7. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
8. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
9. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
10. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
11. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... --  Provista , a proven leader in the supply chain ... Jim Cunniff as the company,s new president and ... to Provista, including most recently serving as the president and ... . He assumed his new role with Provista on May ... Provista," says Jody Hatcher , president, Sourcing and Collaboration ...
(Date:5/4/2017)... MONTREAL , May 4, 2017  Fortuna Fix Inc. (" ... aiming to be the first to eliminate the need for ... autologous cells to treat neurodegenerative diseases. Fortuna ... ("SAB") with Professor Michael Fehlings , MD, PhD; Father ... Hack , MD, MPH; and Professor James Giordano , ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD is dual ... City. He is known for his distinguished expertise and experience in the diagnosis and ... sub-specialty training in treating renovascular disease and aortic aneurysm . He is known ...
(Date:5/24/2017)... ... May 24, 2017 , ... NucleusHealth ... interpretation, has received U.S. Food and Drug Administration (FDA) 510(k) clearance ... and secure cloud platform for medical image management. At the core is patented ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation for ... that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and destroys ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... Course II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As ... latest advancements in his field by attending numerous CE courses each year. His ...
Breaking Medicine News(10 mins):